Parkinson's Progression Markers Initiative Clinical - Scan without dopaminergic deficit cohort (PPMI - SWEDD)
PPMI Clinical enrols prodromal, recently diagnosed Parkinson's Disease (PD) participants and healthy controls. PPMI aims to identify markers of disease progression for use in clinical trials of therapies to reduce the progression of PD disability. The SWEDD cohort included participants who were clinically diagnosed with PD but had a normal Dopamine Transporter Scan on visual inspection. PPMI participants were recruited from 35 clinical sites in North America, Europe, Israel, and Australia. Almost 70 participants completed baseline assessment in 2011 and were followed up every three to six months for 8 years.
Study design
Cohort, Cohort - clinical
Number of participants at first data collection
66 (participants)
Age at first data collection
≥ 30 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2011 (participants)
Primary Institutions
Michael J. Fox Foundation for Parkinson's Research
Links
ppmi-info.org/study-design/study-cohorts
ppmi-info.org/sites/default/files/docs/archives/Amendment-12.pdf
Profile paper DOI
Not available
Funders
Michael J. Fox Foundation for Parkinson's Research
Ongoing?
No
Data types collected
- Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
- Interview – face-to-face
- Interview – phone
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- Self-report questionnaire – unspecified
- None
- Diffusion Tensor Imaging (DTI)
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Single-photon emission computed tomography (SPECT)
- None
Engagement
Keywords
Consortia and dataset groups
